Sukhi and Kiranjit Ghuman face US extradition over cancer drug fraud

A Nottinghamshire businessman and his ex-wife are fighting attempts to send them across the Atlantic to stand trial over allegations of a multi-million-dollar health fraud and drug smuggling scheme, according to legal filings and reports from the Bbc, Yahoo News, and the Nottingham Post. Dr Sukhi Ghuman, who founded the Bingham-based security firm Octavian Group and lives at Syerston Hall near Newark, alongside his ex-wife Kiranjit Ghuman, stands accused of defrauding federal American health programmes by supplying unapproved chemotherapy medications to vulnerable patients.

Prosecutors acting on behalf of the United States government assert that an investigation uncovered a conspiracy spanning several years. According to legal representatives for the US authorities, including Peter Caldwell KC, the scheme involved obtaining cheap, unapproved oncology drugs from overseas suppliers—specifically from India, Sri Lanka, and Turkey—and administering them to cancer patients at clinics controlled by the pair in California and Arizona through their firm Colton Health. US investigators claim that some of the imported medication was out of date and that traces of non-approved drugs were discovered in clinic fridges alongside discarded items.

Media additions

The extradition proceedings at Westminster Magistrates' Court are scheduled to span multiple days, specifically set for a five-day hearing. Legal arguments centre on whether the pair should be surrendered to face charges in the United States, where arrest warrants were originally issued by the District Court of the Southern District of California in San Diego in October 2023. The drug smuggling charge alone carries a maximum sentence of 20 years in custody if found guilty, with the indictment noting the couple and five other defendants face 25 counts in total.

According to the prosecution case presented to the court by Peter Caldwell KC, the clinics caused federal health insurance programmes, including Medicare and Medi-Cal, to be billed as though costly, United States Food and Drug Administration-approved medications were being dispensed. The US indictment claims that more than $9.6m (£7.2m) in fraudulent billing was submitted, resulting in payouts exceeding $2.9m (£2.2m). An additional scheme noted in the extradition request alleges that one of the oncology clinics purchased domestic FDA-approved drugs from medical wholesalers and resold them without proper licensing.

Dr Ghuman has vehemently contested the narrative presented by American authorities. Speaking to regional reporters, he slammed the proceedings as a staggering injustice and argued that the legal battle has devastated his life. He acknowledged that medications had been ordered from reputable global suppliers and approved by the NHS, but noted they lacked approval from the American regulatory agency. He insisted that the drugs sourced from India were chemically identical to US counterparts and that no patients were misled or harmed.

Furthermore, Dr Ghuman maintained that he was never responsible for medical decisions at the clinics, pointing instead to a physician whom he is reportedly suing. He argued that prosecuting support staff with no medical authority, and noting that his former wife held only a nominal title as vice-president and chief financial officer of Colton Health, represents a misuse of resources. He has sought help from the Trump administration and appealed to the US Department of Justice to halt what he calls a flawed and politically motivated prosecution.

The extradition hearing at Westminster Magistrates' Court is scheduled to last five days.